Combined therapy of cyclosporine A and mycophenolate mofetil for the treatment of birdshot retinochoroidopathy: a 12-month follow-up

Abstract

These results suggest that combined IMT with CSA and MM for BSRC is well tolerated and associated with long-term control of inflammation.

Mycophenolic acid in the treatment of birdshot chorioretinopathy: long-term follow-up

“…With regards to functional assessment, it is well known that in BSCR, exclusive BCVA assessment should not be considered as a reliable parameter for evaluating therapy response 7 20 23 24. In the present study, BCVA, visual field and full-field ERG parameters remained stable during the treatment and no worsening of the retinal function was observed.…”

“…However, the outcome of MMF treatment was not analysed separately from the other immunosuppressive drugs. Recently, Cervantes-Castaneda et al 20 presented their results of combined immunosuppressive therapy with cyclosporine A and MMF in patients with BSCR. The authors reported on the control of inflammation in 67.4% of the patients.…”

Safety profile and efficacy of tacrolimus in the treatment of birdshot retinochoroiditis: a retrospective case series review

“…The outcome for treated eyes was better than untreated eyes but the inflammation returned on the discontinuation of therapy. A subsequent report from the same group used combination therapy with mycophenolate mofetil and CSA in an attempt to reduce the possibility of CSA-associated nephrotoxicity 26. There was effective control of inflammation (based on vitritis and angiographic leakage), but a 55% incidence of significant side effects, systemic hypertension being the most common.…”

New concepts in the appraisal and management of birdshot retinochoroiditis, a global perspective

“…There is increasing evidence that aggressive and sustained treatment is probably needed in the majority of patients; [41,42] not more than 10-15 % of patients present a relatively mild course [8]. Once the diagnosis is established, our criterion to treat is the occurrence of visual field defects.…”